> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Novocure's Raised Outlook Implies A Fourth-Quarter Revenue Dip, And The CFO Walks Through Why
- URL: https://www.bullished.co/novocures-raised-outlook-implies-a-fourth-quarter-revenue-dip-and-the-cfo-walks-through-e513a85d/
- Published: 2026-10-29T13:01:19.000Z
- Updated: 2026-10-29T14:55:02.000Z
- Description: The company's $736 million to $743 million revenue guide implies a softer fourth quarter than the $193 million just reported.
- Author: Matteo Parrino
- Tags: Earnings, NVCR, Industry: Healthcare

[Novocure](https://www.bullished.co/tag/nvcr/)'s raised full-year guidance implies fourth-quarter revenue below the quarter it just posted, and CFO Christoph Brackmann said on the company's Thursday earnings call that the outlook is built on repeating the third quarter minus a one-time gain. Novocure, which makes wearable devices that deliver electric fields meant to kill cancer cells, now expects [$736 million to $743 million](https://wtop.com/national/2026/10/novocure-q3-earnings-snapshot/?ref=bullished.co) in 2026 net revenue.

## The step-down math

A JPMorgan analyst said the new range implies fourth-quarter revenue of $185 million to $192 million, under the $193 million recorded in the third quarter, and asked what drives the drop.

Brackmann said the third quarter added about $9 million to the record set in the second. Repeating it in the fourth quarter, less roughly $4.4 million of one-time revenue, gets to about $740 million for the year, around the guidance midpoint. The company then allowed for "some potential risk on collections" alongside some opportunities, he said.

He said the one-time benefit came from higher approval rates in the U.S. and Germany. Management put full-year growth at 12% to 13%.

## Profit path, with a caveat

Third-quarter net revenue rose 16% from a year earlier, driven by a 19% rise in active patients, Brackmann said. Net loss narrowed to $10 million from $37 million, and [adjusted EBITDA](https://seekingalpha.com/news/4660072-novocure-beats-top-line-and-bottom-line-estimates-updates-fy26-outlook?ref=bullished.co) reached $15.7 million, according to coverage of the company's release. Gross margin was 77%, against 73% a year earlier.

Asked by an Evercore ISI analyst whether that profit level is sustainable, Brackmann said results will fluctuate and he wouldn't "want to commit to a straight line on a quarter-to-quarter basis." The fourth quarter is typically hard to estimate, he said, because the company is preparing next year's launches.

## Pancreatic launch hits resistance

Optune Pax, the pancreatic cancer device, ended the quarter with 276 active patients and $3.7 million in net revenue. CEO Frank Leonard said U.S. momentum slowed after the introduction of a rival drug, and that practices are overwhelmed by insurance appeals and skin irritation, which limits the sales team's access.

Optune Lua, for lung cancer, had 255 active patients and $8 million in revenue, with Japan contributing 110 patients and $4 million. Leonard said Japanese reimbursement for Pax is likely in the first quarter of 2027.

The next catalyst is the FDA decision on Optune Maya for brain metastases from non-small cell lung cancer, which management expects by year end.

Management expects an FDA decision on Optune Maya by year end, with a potential launch in early 2027.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [NovoCure beats top-line and bottom-line estimates; updates FY26 outlook | Seeking Alpha](https://seekingalpha.com/news/4660072-novocure-beats-top-line-and-bottom-line-estimates-updates-fy26-outlook?ref=bullished.co) — seekingalpha.com
- [NovoCure: Q3 Earnings Snapshot | 9news.com](https://www.9news.com/article/syndication/associatedpress/novocure-q3-earnings-snapshot/616-a10b892b-59e2-4452-adf4-1b428eb83025?ref=bullished.co) — Associated Press
- [NovoCure: Q3 Earnings Snapshot – WTOP News](https://wtop.com/national/2026/10/novocure-q3-earnings-snapshot/?ref=bullished.co) — wtop.com
- [NovoCure: Q3 Earnings Snapshot](https://www.seattlepi.com/business/novocure-q3-earnings-snapshot-a22500146?ref=bullished.co) — seattlepi.com
- [NovoCure: Q3 Earnings Snapshot | wusa9.com](https://www.wusa9.com/article/syndication/associatedpress/novocure-q3-earnings-snapshot/616-a10b892b-59e2-4452-adf4-1b428eb83025?ref=bullished.co) — Associated Press

### More on Novocure

- [Novocure's Pancreatic Device Ends Quarter With 276 Patients And $3.7 Million In Sales As Rival Drug Crowds Clinics](https://www.bullished.co/novocures-pancreatic-device-ends-quarter-with-276-patients-and-3-7-million-in-sales-as-2c4e1f7b/)
- [Novocure Raises 2026 Revenue Outlook To $736 Million-$743 Million After Record Quarter](https://www.bullished.co/novocure-raises-2026-revenue-outlook-to-736-million-743-million-after-record-quarter-cbe8723b/)
- [Novocure Turns Cash-Flow Positive For Nine Months, With $22.8 Million From Unpaid Bills And A $25 Million Debt Slice Now Due](https://www.bullished.co/novocure-turns-cash-flow-positive-for-nine-months-with-22-8-million-from-unpaid-bills-and-5369ced4/)

[All Novocure (NVCR) coverage →](https://www.bullished.co/tag/nvcr/)